Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts)

American Journal of Cardiology

Volumn 115, Issue 1, 2015, Pages 40-46

  Ashburner, Jeffrey M ^a,b   Go, Alan S ^c   Reynolds, Kristi ^d   Chang, Yuchiao ^a   Fang, Margaret C ^e   Fredman, Lisa ^b   Applebaum, Katie M ^f,g   Singer, Daniel E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c DIVISION OF RESEARCH   (United States)

^d Department of Research and Evaluation Kaiser Permanente Southern California ^*  (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; UNITED STATES; UPPER GASTROINTESTINAL BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; INCIDENCE; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; THROMBOEMBOLISM; TRENDS;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CALIFORNIA; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; THROMBOEMBOLISM; WARFARIN;

EID: 84915748711     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.10.006     Document Type: Article

References (27)

1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
2. M.C. Fang, A.S. Go, Y. Chang, E.M. Hylek, L.E. Henault, N.G. Jensvold, and D.E. Singer Death and disability from warfarin-associated intracranial and extracranial hemorrhages Am J Med 120 2007 700 705
3. L.A. Linkins, P.T. Choi, and J.D. Douketis Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis Ann Intern Med 139 2003 893 900
4. C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, M.D. Ezekowitz, A.J. Camm, J.I. Weitz, B.S. Lewis, A. Parkhomenko, T. Yamashita, and E.M. Antman Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
5. A.S. Go, E.M. Hylek, Y. Chang, K.A. Phillips, L.E. Henault, A.M. Capra, N.G. Jensvold, J.V. Selby, and D.E. Singer Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 290 2003 2685 2692
6. A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro III, H.I. Feldman, J.W. Kusek, P. Eggers, F. Van Lente, T. Greene, J. Coresh CKD EPI A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
7. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
8. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
9. D.E. Singer, Y. Chang, L.H. Borowsky, M.C. Fang, N.K. Pomernacki, N. Udaltsova, K. Reynolds, and A.S. Go A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score J Am Heart Assoc 2 2013 e000250
10. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
11. M.C. Fang, A.S. Go, Y. Chang, L.H. Borowsky, N.K. Pomernacki, N. Udaltsova, and D.E. Singer A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study J Am Coll Cardiol 58 2011 395 401
12. S. Suissa Immortal time bias in observational studies of drug effects Pharmacoepidemiol Drug Saf 16 2007 241 249
13. P. Rosenbaum, and D. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
14. T. Sturmer, K.J. Rothman, J. Avorn, and R.J. Glynn Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution - a simulation study Am J Epidemiol 172 2010 843 854
15. M.C. Fang, A.S. Go, Y. Chang, L.H. Borowsky, N.K. Pomernacki, N. Udaltsova, and D.E. Singer Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants Stroke 43 2012 1795 1799
16. J. Rosand, M.H. Eckman, K.A. Knudsen, D.E. Singer, and S.M. Greenberg The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage Arch Intern Med 164 2004 880 884
17. S. Schulman, R.J. Beyth, C. Kearon, M.N. Levine American College of Chest Physicians Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 257S 298S
18. J.N. Goldstein, S.H. Thomas, V. Frontiero, A. Joseph, C. Engel, R. Snider, E.E. Smith, S.M. Greenberg, and J. Rosand Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage Stroke 37 2006 151 155
19. B.F. Gage, Y. Yan, P.E. Milligan, A.D. Waterman, R. Culverhouse, M.W. Rich, and M.J. Radford Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J 151 2006 713 719
20. S.J. Connolly, J.W. Eikelboom, J. Ng, J. Hirsh, S. Yusuf, J. Pogue, R. de Caterina, S. Hohnloser, R.G. Hart ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable Ann Intern Med 155 2011 579 586
21. J.W. Eikelboom, S.J. Connolly, R.G. Hart, L. Wallentin, P. Reilly, J. Oldgren, S. Yang, and S. Yusuf Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation J Am Coll Cardiol 62 2013 900 908
22. D.E. Singer, Y. Chang, M.C. Fang, L.H. Borowsky, N.K. Pomernacki, N. Udaltsova, and A.S. Go The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann Intern Med 151 2009 297 305
23. T.J. Bungard, W.A. Ghali, F.A. McAlister, A.M. Buchan, A.J. Cave, P.G. Hamilton, L.B. Mitchell, A. Shuaib, K.K. Teo, and R.T. Tsuyuki The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation Can J Cardiol 19 2003 280 284
24. J.P. Casciano, D.E. Singer, W.J. Kwong, E.S. Fox, and B.C. Martin Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use Am J Cardiovasc Drugs 12 2012 313 323
25. M.C. Fang, Y. Chang, E.M. Hylek, J. Rosand, S.M. Greenberg, A.S. Go, and D.E. Singer Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation Ann Intern Med 141 2004 745 752
26. B.F. Gage, M. Boechler, A.L. Doggette, G. Fortune, G.C. Flaker, M.W. Rich, and M.J. Radford Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation Stroke 31 2000 822 827
27. E.M. Hylek, C. Held, J.H. Alexander, R.D. Lopes, R. De Caterina, D.M. Wojdyla, K. Huber, P. Jansky, P.G. Steg, M. Hanna, L. Thomas, L. Wallentin, and C.B. Granger Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes J Am Coll Cardiol 63 2014 2141 2147